Evenity (Romosozumab) Cost in Vermont 2026: Prices, Insurance & Savings
Evenity is the brand name for romosozumab-aqqg, a monoclonal antibody made by Amgen and marketed with UCB. It is FDA-approved for osteoporosis treatment in postmenopausal women at high risk of bone fracture, given as one subcutaneous injection per month for 12 months total. It is not the same drug as denosumab (Prolia), teriparatide (Forteo), or abaloparatide (Tymlos), which are discussed below only for cost comparison.
The honest answer to "what does it cost in Vermont" is that there is no separate Vermont price for a single-source branded biologic like this. Amgen sets one national list price (wholesale acquisition cost, or WAC), and that number does not vary by state. What actually changes by patient, and does vary within Vermont, is how much of that list price a given person pays out of pocket, which depends on insurance type, formulary tier, prior authorization outcome, and eligibility for manufacturer assistance. That distinction, not a state-specific dollar figure, is the useful framing for this page.
Because this draft could not verify current 2026 pricing, Vermont Medicaid policy text, or specific insurer formulary placement against a primary source, those figures are flagged below as needing direct verification rather than stated as fact.
The core, quotable answer
Romosozumab (Evenity) is dosed as a monthly subcutaneous injection for 12 months, is FDA-approved only for postmenopausal women at high fracture risk, and carries a boxed warning limiting its use in people with a myocardial infarction or stroke in the prior year. Its list price is set nationally by the manufacturer rather than by state, so a Vermont patient's actual cost depends primarily on insurance type, prior authorization approval, and eligibility for the manufacturer's copay program, not on geography. Readers should verify current price, formulary tier, and prior authorization criteria directly with their pharmacy, insurer, or Vermont Medicaid before relying on any specific dollar figure, since these details change over time and were not independently confirmed for this article.
What is stable versus what changes
Stable, federally anchored facts (unlikely to change without an FDA action):
- FDA-approved indication: osteoporosis treatment in postmenopausal women at high fracture risk, per the FDA label.
- Dosing: one monthly subcutaneous injection, 12 doses total, per the same label.
- Boxed warning: increased risk of myocardial infarction, stroke, and cardiovascular death; contraindicated within 12 months of a heart attack or stroke.
- Mechanism: sclerostin inhibition, which both stimulates bone formation and reduces bone resorption.
- Legal framework for compounding: Section 503A of the Federal Food, Drug, and Cosmetic Act permits patient-specific compounding by state-licensed pharmacies, per FDA guidance and the FDA's compounding Q&A.
Volatile facts that must be checked at the time a patient needs them:
- Current wholesale acquisition cost and any Vermont pharmacy cash price.
- Vermont Medicaid's current preferred drug list status, step-therapy requirements, and prior authorization turnaround time.
- Which Vermont commercial insurers cover the drug, on what tier, and with what coinsurance.
- Whether Amgen's Assist 360 copay program is active, its eligibility rules, and its current maximum annual benefit.
- Whether any specific Vermont 503A pharmacy currently compounds romosozumab, and at what price.
- Vermont's telehealth parity requirements as currently codified in state law.
Vermont Medicaid: the general pattern, not confirmed specifics
Public and commercial payers typically require prior authorization for high-cost injectable osteoporosis biologics, and step therapy through an oral bisphosphonate (such as alendronate) is a common requirement before an anabolic agent like romosozumab is approved. Clinical documentation commonly requested includes a DXA scan showing significant bone loss, a history of fragility fracture, or documented intolerance or failure of first-line therapy.
This general pattern is plausible for Vermont Medicaid but this article cannot confirm Vermont's specific 2026 criteria, PA turnaround time, or appeal process from the sources available. A prescriber's office or Vermont Medicaid's published pharmacy policy is the correct place to confirm current requirements before submitting a request.
Commercial insurance: what to expect, and what to verify
Specialty biologics like romosozumab are usually placed on a higher specialty tier by commercial plans, which typically means coinsurance rather than a flat copay, along with a prior authorization requirement. Guideline bodies that classify treatments by fracture-risk severity (for example, categorizing "very high risk" patients as those with a recent fracture, multiple fractures, or very low bone density) are often cited in prior authorization letters because payers use similar risk categories to decide whether an anabolic agent is appropriate before an antiresorptive drug has been tried.
This draft does not have a verified, current source confirming which specific Vermont insurers cover Evenity, on which tier, or with what coinsurance range for 2026. Patients and prescribers should request a benefits investigation directly from the insurer before assuming coverage.
Manufacturer support: Amgen Assist 360
Amgen operates a patient support program, described on its own site, that includes benefits verification, injection training, and a copay assistance option for eligible commercially insured patients. Copay assistance programs of this type are generally restricted to patients with commercial insurance; people enrolled in Medicare, Medicaid, or other government insurance are typically not eligible for manufacturer copay cards, though separate manufacturer patient-assistance (free-drug) programs for the uninsured sometimes exist. This article cannot confirm the current 2026 eligibility rules or benefit maximum for Assist 360; confirm directly with Amgen before counting on a specific savings amount.
Compounded romosozumab: what the law allows and what it does not guarantee
Section 503A of the FD&C Act permits a state-licensed pharmacy to compound a patient-specific preparation under a valid prescription, and the FDA is explicit that compounded drugs are not the same as FDA-approved products: they are not evaluated by the FDA for safety, effectiveness, or manufacturing consistency the way an approved biologic like Evenity is (FDA compounding Q&A; Section 503A text).
Verification checklist: what is safe to trust today versus what needs a fresh check
| Fact category | Example claim | How stable is it | Before using it, verify with |
|---|---|---|---|
| FDA-approved indication and dosing | Monthly injection, 12 doses, for high-risk postmenopausal osteoporosis | Stable unless FDA changes the label | Current FDA label |
| Boxed warning and contraindication | Not for use within 12 months of MI or stroke | Stable unless FDA changes the label | Current FDA label |
| Legal basis for compounding | 503A allows patient-specific compounding by licensed pharmacies | Stable federal statute | FDA compounding pages |
| Whether a specific compound is bioequivalent or FDA-evaluated | "Compounded romosozumab works the same as Evenity" | Not established; do not assume | Prescriber and compounding pharmacy directly, on a per-batch basis |
| National list price / WAC | Dollar amount per monthly dose | Changes periodically, sometimes yearly | Manufacturer or a current, dated pricing source |
| Vermont Medicaid PA criteria | Step therapy, T-score threshold, turnaround time | Reviewed and can change with plan-year updates | Vermont Medicaid's current pharmacy policy documents |
| Specific insurer's tier and coinsurance | Which Vermont commercial plans cover it, and how | Plan-year dependent | The individual insurer's specialty pharmacy benefits line |
| Manufacturer copay program terms | Eligibility, maximum annual benefit | Program terms can change | Amgen Assist 360 directly |
| Vermont telehealth prescribing rules | Whether an initial visit can be fully virtual | State law and payer parity rules can change | Vermont's current telehealth statute and payer policy |
This checklist is meant to be used at the point of care: anything in the left-hand rows below "FDA-approved indication and dosing" and "legal basis for compounding" should be re-verified against a current, dated source before a patient or prescriber relies on it, rather than assumed to still be accurate from this article.
Cardiovascular safety: why this matters for who is a candidate at all
Romosozumab carries an FDA black box warning regarding myocardial infarction, stroke, and cardiovascular mortality. This warning stems from a pivotal comparative study with alendronate showing a numerically elevated rate of major adverse cardiovascular events in romosozumab-treated patients during year one. Consequently, romosozumab is contraindicated in patients with myocardial infarction or stroke in the prior 12 months. Cardiovascular risk assessment is mandatory before initiating treatment. Teriparatide and abaloparatide represent anabolic alternatives for patients with substantial cardiovascular risk, as neither carries a comparable black box cardiovascular warning. However, both agents have distinct safety considerations, including treatment duration restrictions based on animal osteosarcoma signals, warranting individualized discussion. This represents general prescribing guidance only and should not replace individualized risk counseling conducted by the prescribing clinician.
Cost context relative to other osteoporosis drugs
Romosozumab, teriparatide, and abaloparatide are all injectable anabolic (bone-building) agents and are generally priced far above oral generic bisphosphonates such as alendronate, which typically costs well under $50 a month as a generic. Romosozumab's approved course is 12 months, shorter than the typical 18-to-24-month course for teriparatide or abaloparatide, which affects total drug exposure and total cost even when monthly prices differ. Denosumab (Prolia), an antiresorptive rather than anabolic drug, is dosed every six months rather than monthly. This draft does not have a verified, dated source for exact current list prices across these drugs and does not state specific dollar comparisons; a pharmacist or current pricing database should be consulted for up-to-date figures.
A consistent finding across the drug's pivotal trials is that stopping romosozumab without transitioning to a follow-on antiresorptive drug (commonly denosumab or a bisphosphonate) leads to loss of the bone density gained during treatment within about a year. This means the real cost of a romosozumab course, for planning purposes, should include the follow-on antiresorptive drug rather than treating the 12-month romosozumab course as the full treatment cost.
Evidence boundary
Established: Romosozumab's FDA-approved indication, its 12-month monthly dosing schedule, its boxed cardiovascular warning, and the legal existence of 503A compounding pathways are all confirmed by the FDA label and FDA compounding guidance cited above. The general clinical pattern that anabolic osteoporosis biologics require step therapy and prior authorization from most U.S. payers, including Medicaid programs, is a well-established feature of specialty drug coverage generally.
Plausible but not confirmed in this draft: The specific dollar list price for 2026, Vermont Medicaid's exact current prior authorization criteria and appeal timelines, which named Vermont commercial insurers cover the drug and on what tier, the current terms of the Amgen Assist 360 program, and the current availability or price of compounded romosozumab at any specific Vermont pharmacy.
Not established: That a compounded version of romosozumab is bioequivalent, equally safe, or equally effective compared with FDA-approved Evenity. That claim is not something 503A compounding status implies, and it is not established in the sources reviewed for this article.
Questions worth asking before starting treatment
Does my insurance require step therapy first? Many payers, including Medicaid programs, require documented use or failure of an oral bisphosphonate before approving an anabolic agent. Ask your prescriber's office to confirm your plan's specific requirement rather than assuming it based on general patterns described here.
Am I a candidate given my cardiovascular history? Anyone with a heart attack or stroke in the past 12 months should not receive this drug per the FDA label; this is a screening question your prescriber should ask directly, not something to self-assess.
What happens after the 12 monthly doses end? Plan for a follow-on antiresorptive medication with your prescriber before starting, since stopping without one is associated with loss of the bone density gained during treatment.
Is a compounded version really a lower-risk lower-cost option? It may cost less, but it has not undergone the same FDA evaluation for safety, effectiveness, or manufacturing consistency as the approved product. That tradeoff should be discussed explicitly with the prescriber, not decided on price alone.
When to seek urgent care
Anyone experiencing chest pain, sudden weakness or numbness, slurred speech, or other possible signs of a heart attack or stroke while on or after starting romosozumab should seek emergency care immediately rather than waiting for a scheduled follow-up.
References
- Evenity (romosozumab-aqqg) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf
- Section 503A of the Federal Food, Drug, and Cosmetic Act. U.S. Food and Drug Administration. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act
- Compounding and the FDA: questions and answers. U.S. Food and Drug Administration. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
This article is a draft for editorial and qualified medical review. It has not yet received clinical sign-off, and dollar figures, Vermont Medicaid policy details, and insurer-specific terms described as unverified above should be confirmed against current, dated sources before publication or use in patient counseling.